Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
Fiche publication
Date publication
mai 2018
Journal
Breast cancer (Tokyo, Japan)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Pivot X, Im SA, Guo M, Marmé F
Lien Pubmed
Résumé
This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m on days 1-14 (21-day cycles). This analysis included 392 patients. Median overall survival was longer in patients receiving eribulin compared with capecitabine (16.1 vs 13.5 months, respectively; HR 0.77, P = 0.026). Median progression-free survival and response rates were similar between arms. Both treatments had manageable safety profiles.
Mots clés
Capecitabine, Eribulin, Metastatic breast cancer, Overall survival, Subgroup analysis
Référence
Breast Cancer. 2018 May;25(3):370-374